And right now, the buzz around GLP-1 medications like Tirzepatide is deafeningfor good reason
And for patients with concurrent fatty liver disease, the data is pointing toward a level of efficacy we have not seen before from any medication
The Investment Opportunity for Weight Loss Drugs Research forecasts that the GLP-1 market will exceed $130 billion by 2030, driven equally by diabetes and obesity usage
Youve invested in this treatment, both financially and emotionally
Our GHK-CU is verified at 99% purity via HPLC and Mass Spectrometry, with a Certificate of Analysis available for each batch
The medication appears to affect central appetite pathways, with GLP-1 receptors found in brain regions responsible for appetite regulation, including the hypothalamus